145 related articles for article (PubMed ID: 32509959)
1. Baseline NT-proBNP and responsiveness to autonomic regulation therapy in patients with heart failure and reduced ejection fraction.
Anand I; Ardell JL; Gregory D; Libbus I; DiCarlo L; Premchand RK; Sharma K; Mittal S; Monteiro R
Int J Cardiol Heart Vasc; 2020 Aug; 29():100520. PubMed ID: 32509959
[TBL] [Abstract][Full Text] [Related]
2. Advances in Our Clinical Understanding of Autonomic Regulation Therapy Using Vagal Nerve Stimulation in Patients Living With Heart Failure.
Konstam MA; Mann DL; Udelson JJE; Ardell JL; De Ferrari GM; Cowie MR; Klein HU; Gregory DD; Massaro JM; Libbus I; DiCarlo LA; Butler J; Parker JD; Teerlink JR
Front Physiol; 2022; 13():857538. PubMed ID: 35530511
[TBL] [Abstract][Full Text] [Related]
3. Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEM-HF, INOVATE-HF, and NECTAR-HF.
Anand IS; Konstam MA; Klein HU; Mann DL; Ardell JL; Gregory DD; Massaro JM; Libbus I; DiCarlo LA; Udelson JJE; Butler J; Parker JD; Teerlink JR
ESC Heart Fail; 2020 Feb; 7(1):75-83. PubMed ID: 31984682
[TBL] [Abstract][Full Text] [Related]
4. Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials.
Coats AJS; Abraham WT; Zile MR; Lindenfeld JA; Weaver FA; Fudim M; Bauersachs J; Duval S; Galle E; Zannad F
Eur J Heart Fail; 2022 Sep; 24(9):1665-1673. PubMed ID: 35713888
[TBL] [Abstract][Full Text] [Related]
5. Persistent Autonomic Engagement and Cardiac Control After Four or More Years of Autonomic Regulation Therapy Using Vagus Nerve Stimulation.
Libbus I; Premchand RK; Sharma K; Mittal S; Monteiro R; Amurthur B; KenKnight BH; DiCarlo LA; Anand IS
Front Physiol; 2022; 13():853617. PubMed ID: 35360224
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic responsiveness to vagus nerve stimulation in patients receiving beta-blockade for heart failure with reduced ejection fraction.
Dede E; Gregory DD; Ardell JL; Libbus I; DiCarlo LA; Premchand RK; Sharma K; Mittal S; Monteiro R; Anand IS; Düngen HD
Int J Cardiol Heart Vasc; 2021 Dec; 37():100888. PubMed ID: 34754899
[TBL] [Abstract][Full Text] [Related]
8. Non-pharmacologic autonomic neuromodulation for treatment of heart failure: A systematic review and meta-analysis of randomized controlled trials.
Ahmed M; Nudy M; Bussa R; Weigel F; Naccarelli G; Maheshwari A
Trends Cardiovasc Med; 2024 Feb; 34(2):101-107. PubMed ID: 36202286
[TBL] [Abstract][Full Text] [Related]
9. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
[TBL] [Abstract][Full Text] [Related]
10. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
Ezekowitz JA; O'Connor CM; Troughton RW; Alemayehu WG; Westerhout CM; Voors AA; Butler J; Lam CSP; Ponikowski P; Emdin M; Patel MJ; Pieske B; Roessig L; Hernandez AF; Armstrong PW
JACC Heart Fail; 2020 Nov; 8(11):931-939. PubMed ID: 33039447
[TBL] [Abstract][Full Text] [Related]
11. Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure: results of the ANTHEM-HF trial.
Premchand RK; Sharma K; Mittal S; Monteiro R; Dixit S; Libbus I; DiCarlo LA; Ardell JL; Rector TS; Amurthur B; KenKnight BH; Anand IS
J Card Fail; 2014 Nov; 20(11):808-16. PubMed ID: 25187002
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
[TBL] [Abstract][Full Text] [Related]
13. N-terminal pro-brain natriuretic peptide (NT-proBNP) release in children with vagus nerve stimulation. A prospective case series.
Rauchenzauner M; Haberlandt E; Ortler M; Tatarczyk T; Laimer M; Trinka E; Luef G
J Neurol; 2008 Jul; 255(7):980-5. PubMed ID: 18581038
[TBL] [Abstract][Full Text] [Related]
14. Background pharmacological therapy in the ANTHEM-HF: comparison to contemporary trials of novel heart failure therapies.
Premchand RK; Sharma K; Mittal S; Monteiro R; Libbus I; Ardell JL; Gregory DD; KenKnight BH; Amurthur B; DiCarlo LA; Anand IS
ESC Heart Fail; 2019 Oct; 6(5):1052-1056. PubMed ID: 31339232
[TBL] [Abstract][Full Text] [Related]
15. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction.
Januzzi JL; Ahmad T; Mulder H; Coles A; Anstrom KJ; Adams KF; Ezekowitz JA; Fiuzat M; Houston-Miller N; Mark DB; Piña IL; Passmore G; Whellan DJ; Cooper LS; Leifer ES; Desvigne-Nickens P; Felker GM; O'Connor CM
J Am Coll Cardiol; 2019 Sep; 74(9):1205-1217. PubMed ID: 31466618
[TBL] [Abstract][Full Text] [Related]
16. Vagus Nerve Stimulation Provides Multiyear Improvements in Autonomic Function and Cardiac Electrical Stability in the ANTHEM-HF Study.
Nearing BD; Anand IS; Libbus I; Dicarlo LA; Kenknight BH; Verrier RL
J Card Fail; 2021 Feb; 27(2):208-216. PubMed ID: 33049374
[TBL] [Abstract][Full Text] [Related]
17. Baroreflex activation therapy in patients with heart failure with reduced ejection fraction: a single-centre experience.
Blanco C; Madej T; Mangner N; Hommel J; Grimm S; Knaut M; Linke A; Winzer EB
ESC Heart Fail; 2023 Dec; 10(6):3373-3384. PubMed ID: 37667319
[TBL] [Abstract][Full Text] [Related]
18. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.
Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y
Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958
[TBL] [Abstract][Full Text] [Related]
19. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
Jhund PS; Anand IS; Komajda M; Claggett BL; McKelvie RS; Zile MR; Carson PE; McMurray JJ
Eur J Heart Fail; 2015 Aug; 17(8):809-17. PubMed ID: 25921853
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.
Kristensen SL; Jhund PS; Mogensen UM; Rørth R; Abraham WT; Desai A; Dickstein K; Rouleau JL; Zile MR; Swedberg K; Packer M; Solomon SD; Køber L; McMurray JJV;
Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29018174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
